Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma
← catalyst calendarNCT05097287 · readout in 208 d
Sponsored by Sanofi (industry) · SNY — their whole pipeline →. With Regeneron Pharmaceuticals.
Phase
Phase 4
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
1,339actual
Sites
249
Countries
Belgium, Brazil, Bulgaria +20
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-12-16 | actual | When the study began enrolling |
| Primary completion | 2027-03-16 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-06-08 | estimated | The whole study's end, after follow-up |
| First posted | 2021-10-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-16 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Asthma
Interventions
- Drug: Dupilumab
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFRate of change from week 8 to week 52 on post-BD FEV1 slope in FeNO population
measured Week 8 to Week 52
Publications
- PMID 36891077 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed